Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Alvotech Swiss AG
Sponsor

Alvotech Swiss AG

Thurgauerstrasse 54, 8050

About the sponsor

Clinical research includes moderate to severe active ulcerative colitis, with interest in biologic treatment pathways and biosimilar development for immune-mediated intestinal inflammation.

  • Ulcerative colitis
  • Biologic therapy
  • Biosimilar medicines

The sponsor’s work in this area is centred on therapeutic options for chronic gastrointestinal inflammation and related immune disease management.

About Specializations

Alvotech Swiss AG runs clinical trials in conditions such as Diabetic retinal oedema, Malignant melanoma stage III, Acute haemorrhagic ulcerative colitis, Diabetic retinopathy, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Malignant melanoma stage III

Recruiting

A Randomized Double‑Blind Study of Pharmacokinetic Similarity of AVT32‑DRL_PB and Pembrolizumab in Patients with Resected Stage IIB‑C‑III Melanoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Alvotech Swiss AG

Diabetic retinal oedema

Recruiting

A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Alvotech Swiss AG

Acute haemorrhagic ulcerative colitis

Not recruiting

Study Comparing AVT16 and Vedolizumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Alvotech Swiss AG

Diabetic retinal oedema+4

Not recruiting

Study on the Safety and Use of AVT06 (Aflibercept) for Patients with Chorioretinal Vascular Diseases

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Alvotech Swiss AG

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.